AI assistant
ArcticZymes Technologies — Board/Management Information 2017
Sep 12, 2017
3538_rns_2017-09-12_4c24422b-df0d-4ac3-a357-6dd9afd55154.html
Board/Management Information
Open in viewerOpens in your device viewer
Biotec Pharmacon appoints new CEO
Biotec Pharmacon appoints new CEO
(Tromsø 12. September 2017) Biotec Pharmacon ASA (OSE:BIOTEC) is pleased to
announce that the company has hired Mr. Christian Jørgensen as the new CEO of
Biotec Pharmacon ASA.
Christian has a MBA from INSEAD and MSc. Econ. from the University of
Copenhagen. He has extensive background from the global healthcare industry,
with positions as General Manager for Baxter Healthcare in Western Europe,
Executive Vice President at Coloplast and President for Hill-Rom's European
business.
Christian will commence in his position on 2 October 2017 and Svein Lien will
resign from his position as of the same date, and become available as a
consultant for a period going forward.
"After Svein decided to resign as a CEO, the Board has thoroughly searched the
Norwegian and the international market for suitable candidates to take the helm
of Biotec. We are therefore very pleased to announce Christian Jørgensen, who is
a very experienced international leader of several biotech companies, as the new
CEO. We are confident that Christian will preserve and develop Biotec Phamacon's
commercial opportunities further and to be a key driver of strategic initiatives
that will enhance shareholder value going forward. I would also like to use this
opportunity to thank Svein Lien for his efforts to build Biotec Pharmacon to
become a valued player in the advanced enzyme business and to build a broad
platform of opportunities with the beta-glucan technology. ", says Erik Thorsen,
Chairman of the Board in Biotec Pharmacon ASA.
For additional information:
Erik Thorsen
Chairman of the Board
+47 907 56 685
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel
immunomodulating products, including Woulgan®, a premium priced product in the
advanced wound care market. ArcticZymes develops, produces and markets enzymes
of marine origin used in molecular DNA technologies and diagnostics.